AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Gamma-aminobutyric acid type B receptor subunit 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UBS5

UPID:

GABR1_HUMAN

Alternative names:

-

Alternative UPACC:

Q9UBS5; B0UXY7; O95375; O95468; O95975; O96022; Q5STL4; Q5SUJ8; Q5SUL3; Q71SG6; Q86W60; Q9UQQ0

Background:

Gamma-aminobutyric acid type B receptor subunit 1 (GABBR1) is a pivotal component of the GABA receptor, a heterodimeric G-protein coupled receptor essential for neurotransmission. GABBR1, in partnership with GABBR2, mediates the inhibitory effects of GABA by regulating various downstream effectors, including adenylate cyclase and potassium channels. This regulation is crucial for maintaining synaptic transmission, influencing neuronal excitability, and modulating neurotransmitter release.

Therapeutic significance:

Understanding the role of Gamma-aminobutyric acid type B receptor subunit 1 could open doors to potential therapeutic strategies. Its involvement in synaptic inhibition, long-term potentiation, and antinociception highlights its potential as a target for treating neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.